GlassScriptPhysician profile
Michelle M Thomson
NPI 1639440936
$990.66
in general payments reported to CMS, 2019-2025
16 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $213 · 2023: $131 · 2024: $421 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $249.95 | 2024 | Enhertu |
| Glaxosmithkline, LLC. | $126.83 | 2023-2024 | Zejula, Jemperli |
| Daiichi Sankyo INC. | $125.00 | 2025 | Enhertu |
| Gilead Sciences, INC. | $100.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $86.12 | 2022-2024 | |
| Genentech USA, INC. | $61.25 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $53.67 | 2022-2023 | Imbruvica |
| Array Biopharma INC | $34.73 | 2024 | Tukysa, Braftovi, Mektovi |
| Amgen INC. | $24.13 | 2022 | |
| Eisai INC. | $23.96 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $21.26 | 2023 | Opdivo |
| Pfizer INC. | $20.27 | 2022 | |
| Karyopharm Therapeutics INC. | $18.57 | 2023 | Xpovio |
| Incyte Corporation | $18.06 | 2022 | |
| Pharmacosmos Therapeutics INC. | $14.42 | 2024 | Cosela |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Thomson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.